PMID- 22198298
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20220331
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Print)
IS  - 1359-6446 (Linking)
VI  - 17
IP  - 9-10
DP  - 2012 May
TI  - Understanding latent tuberculosis: the key to improved diagnostic and novel 
      treatment strategies.
PG  - 514-21
LID - 10.1016/j.drudis.2011.12.013 [doi]
AB  - Treatment of latent tuberculosis (LTBI) is a vital component of tuberculosis (TB) 
      elimination but is not efficiently implemented with currently available 
      diagnostics and therapeutics. The tuberculin skin test and interferon-gamma release 
      assays can inform that infection has occurred, but do not prove that it persists. 
      Treatment of LTBI with isoniazid targets actively replicating bacilli but not 
      non-replicating populations, prolonging treatment duration. Developing more 
      predictive diagnostic tests and treatments of shorter duration requires a greater 
      understanding of the biology of LTBI, from both host and bacillary perspectives. 
      In this article, we discuss the basis of current diagnosis and treatment of LTBI 
      and review recent developments in understanding the biology of latency that might 
      enable future improved diagnostic and treatment strategies.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Esmail, Hanif
AU  - Esmail H
AD  - Clinical Infectious Diseases Research Initiative, Institute of Infectious 
      Diseases and Molecular Medicine, University of Cape Town, Observatory 7925, South 
      Africa. h.esmail@imperial.ac.uk
FAU - Barry, Clifton E 3rd
AU  - Barry CE 3rd
FAU - Wilkinson, Robert J
AU  - Wilkinson RJ
LA  - eng
GR  - R01 HL075845/HL/NHLBI NIH HHS/United States
GR  - 090170/WT_/Wellcome Trust/United Kingdom
GR  - 37822/WT_/Wellcome Trust/United Kingdom
GR  - 088316/Wellcome Trust/United Kingdom
GR  - 084323/Wellcome Trust/United Kingdom
GR  - MC_U117588499/MRC_/Medical Research Council/United Kingdom
GR  - ZIA AI001067-04/Intramural NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - U117588499(88499)/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20111220
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Antitubercular Agents)
RN  - 0 (Tuberculosis Vaccines)
SB  - IM
MH  - Animals
MH  - Antitubercular Agents/therapeutic use
MH  - Humans
MH  - Interferon-gamma Release Tests
MH  - Latent Tuberculosis/*diagnosis/*therapy
MH  - Tuberculin Test
MH  - Tuberculosis Vaccines/therapeutic use
PMC - PMC3443737
MID - NIHMS349316
EDAT- 2011/12/27 06:00
MHDA- 2012/09/05 06:00
PMCR- 2013/05/01
CRDT- 2011/12/27 06:00
PHST- 2011/08/31 00:00 [received]
PHST- 2011/12/04 00:00 [revised]
PHST- 2011/12/13 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
PHST- 2013/05/01 00:00 [pmc-release]
AID - S1359-6446(11)00440-5 [pii]
AID - 10.1016/j.drudis.2011.12.013 [doi]
PST - ppublish
SO  - Drug Discov Today. 2012 May;17(9-10):514-21. doi: 10.1016/j.drudis.2011.12.013. 
      Epub 2011 Dec 20.